[1]  Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories[J]. Neurobiol Aging, 1997, 18(4): 351-357.

[2]  Selkoe D J. Alzheimer’s disease: genes, proteins, and therapy[J]. Physiol Rev, 2001, 81(2): 741-766.

[3]  Chishti M A, Yang D S, Janus C, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695[J]. J Biol Chem, 2001, 276(24): 21 562-21 570. 

[4]  Sturchler P C, Abramowski D, Duke M, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology[J]. Proc Natl Acad Sci USA, 1997, 94(24): 13 287-13 292.

[5]  Valk J, Barkhof F, Scheltens P, et al. Magnetic Resonance in Dementia[M]. Heidelberg/Berlin/New York: Springer-Verlag, 2002.

[6]  Delatour B, Guegan M, Volk A, et al. In vivo MRI and histological evaluation of brain atrophy in APP/PS1 transgenic mice[J]. Neurobiol Aging, 2006, 27(6): 835-847.

[7]  Lee S P, Falangola M F, Nixon R A, et al. Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer’s disease using MR microscopy without contrast reagents[J]. Magn Reson Med, 2004, 52(3): 538-544.

[8]  Jack Jr C R, Garwood M, Wengenack T M, et al. In vivo visualization of Alzheimer’s amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent[J]. Magn Reson Med, 2004, 52(6): 1 263-1 271.

[9]  Falangola M F, Lee S P, Nixon R A, et al. Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice[J]. Neurochem Res, 2005, 30(2): 201-205.

[10]  Huesgen C T, Burger P C, Crain B J, et al. In vitro MR microscopy of the hippocampus in Alzheimer’s disease[J]. Neurology, 1993, 43(1): 145-152.

[11]  Benveniste H, Einstein G, Kim K R, et al. Detection of neuritic plaques in Alzheimer’s disease by magnetic resonance microscopy[J]. Proc Natl Acad Sci USA, 1999, 96(24): 14 079-14 084.

[12]  Zaim Wadghiri Y, Sigurdsson E M, Sadowski M, et al. Detection of Alzheimer’s amyloid in transgenic mice using magnetic resonance microimaging[J]. Magn Reson Med, 2003, 50(2): 293-302.

[13]  Haley A P, Knight-Scott J, Fuchs K L, et al. Shortening of hippocampus spin-spin relaxation time in probable Alzheimer’s disease: a ¹H magnetic resonance sprctroscopy study[J]. Neurosci Lett, 2004, 362(3): 167-170.

[14]  Laakso M P, Partanen K, Soininen H, et al. MR T₂ relaxometry in Alzheimer’s disease and age-associated memory impairment[J]. Neurobiol Aging, 1996, 17(4): 535-540.

[15]  Kirsch S J, Jacobs R W, Butcher L L, et al. Prolongation of magnetic resonance T₂ time in hippocampus of human patients marks the presence and severity of Alzheimer’s disease[J]. Neurosci Lett, 1992, 134(2): 187-190.

[16]  Helpern J A, Lee S P, Falangola M F, et al. MRI assessment of neuropathology in a transgenic mouse model of Alzheimer’s disease[J]. Magn Reson Med, 2004, 51(4): 794-798. 

[17]  Falangola M F, Ardekani B A, Lee S P, et al. Application of a non-linear image registration algorithm to quantitative analysis of T₂ melaxation time in transgenic mouse medels of AD[J]. J Neurosci Methods, 2005, 144(1): 91-97.

[18]  El Tayara N E, Delatour B, Cudennec C L, et al. Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer’s disease[J]. Neurobiol Disease, 2006, 22(1): 199-208.

[19]  Dhenain M, El Tayara N E, Wu T D, et al. Characterization of in vivo MRI detectable thalamic amyloid plaques from APP/PS1 mice[J]. Neurobiol Aging, 2009, 30(1): 41-53.